ACOG (Alpha Cognition) PensionAndRetirementBenefit : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition PensionAndRetirementBenefit?

Alpha Cognition's PensionAndRetirementBenefit for the quarter that ended in Mar. 2025 was $0.00 Mil.

Alpha Cognition PensionAndRetirementBenefit Historical Data

The historical data trend for Alpha Cognition's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition PensionAndRetirementBenefit Chart

Alpha Cognition Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

PensionAndRetirementBenefit

Alpha Cognition Quarterly Data
	Jan20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
PensionAndRetirementBenefit	Get a 7-Day Free Trial														-	-	-	-	-

Alpha Cognition PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.

Alpha Cognition Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (NAS:ACOG) » Definitions » PensionAndRetirementBenefit

Comparable Companies

Traded in Other Exchanges

N/A

Address

1200 - 750 West Pender Street, Vancouver, BC, CAN, V6C 2T8

Website

https://www.alphacognition.com

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.